Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Lipocine Inc. (LPCN) director John W. Higuchi purchased 12,561 shares of common stock on September 28, 2026, at $2.16 per share; the transaction is described as a purchase in the open market or a private transaction. His directly held position after the purchase was 216,358 shares. No Rule 10b5-1 plan is reported.
Lipocine Inc. (LPCN) filed a report stating that on September 16, 2026 it presented at the H.C. Wainwright 28th Annual Global Investor Conference in New York City, held September 14–16, 2026. The company furnished its conference presentation as Exhibit 99.1 and incorporated it by reference into this report.
The filing also lists a Cover Page Interactive Data File as Exhibit 104. No financial results, guidance, or transactional events are described; the disclosure centers on making Lipocine’s investor presentation publicly available to the market.
Lipocine Inc. (LPCN) announced the initiation of BLOOM, a Phase 3 outpatient study of LPCN 1154, an oral brexanolone candidate for postpartum depression, with approximately 120 participants and first dosing expected in early Q4 2026. LPCN 1154 is being developed as a 48-hour, at-home treatment aimed at rapid symptom relief.
BLOOM incorporates U.S. FDA feedback and is designed to support a potential New Drug Application under the 505(b)(2) pathway, using the same dosing regimen and a HAM-D17 primary endpoint at 60 hours. The design adds site- and data-quality controls and prespecified sensitivity analyses, following a prior Phase 3 trial that did not meet its primary endpoint but showed exploratory efficacy signals when data from one anomalous high-enrolling site were excluded; those findings are described as exploratory and non-confirmatory. Lipocine reports $23.3 million in unrestricted cash, cash equivalents and marketable securities as of June 30, 2026 and expects existing resources to fund BLOOM, with anticipated average cash use of about $1 million per month during study execution.
Lipocine Inc. (LPCN) reported that on September 8, 2026 it agreed with A.G.P./Alliance Global Partners to modify the compensation terms under their existing Sales Agreement dated April 26, 2024. The Sales Agent’s fee on sales made under this agreement will be up to 3.0%, subject to further adjustment by Lipocine and the Sales Agent.
Lipocine Inc. (LPCN) announced that management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference, held in person and virtually from September 14–16, 2026, in New York City. The company’s presentation is scheduled for September 16, 2026, at 10:00 a.m.
The presentation will be webcast live, with a replay available in the Events section of Lipocine’s website for 90 days. Lipocine describes itself as a specialty biopharmaceutical company developing orally delivered therapeutics, with a pipeline including candidates for postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms, and prevention of preterm birth, as well as TLANDO, an FDA‑approved oral testosterone prodrug for hypogonadism.
Lipocine Inc. (LPCN) filed an amendment to report that its Board of Directors appointed Michael Grissinger to serve as a member of the Compensation Committee. The Board made this committee appointment on August 18, 2026, following his earlier appointment to the Board reported on August 3, 2026.
For his additional duties on the Compensation Committee, Mr. Grissinger is eligible to receive an extra $7,500 per year in compensation. The report is signed by President and Chief Executive Officer Mahesh V. Patel on August 21, 2026.
Squadron Master Fund LP and related parties report a significant ownership stake in Lipocine Inc. The group, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, reports beneficial ownership of 810,000 shares of Lipocine common stock, representing 9.8% of the outstanding shares, based on 8,244,253 shares outstanding as of May 6, 2026. Voting and dispositive power over these shares is reported as shared, with no sole voting or dispositive power. The reporting persons state that the Funds have the right to receive dividends and sale proceeds and expressly disclaim beneficial ownership under Rule 13d-4.
Lipocine director Michael Grissinger received a grant of 2,000 stock options on August 3, 2026, each for Lipocine common stock at an exercise price of $2.11 per share and expiring on August 3, 2036. The options are subject to vesting: one-third of the shares vest on the one-year anniversary of August 3, 2027, and the remaining two-thirds vest monthly on a prorata basis over the following two years. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Lipocine Inc. filed an initial beneficial ownership report for Michael Grissinger, who is identified as a director but not an officer or ten percent owner. The filing reports no equity holdings or insider transactions for him at this time.
Lipocine Inc. reported Q2 2026 results highlighted by increased liquidity and ongoing investment in its development pipeline. As of June 30, 2026, it held $23.3 million in unrestricted cash, cash equivalents and marketable investment securities, up from $14.9 million at December 31, 2025. For the quarter, net loss was $2.6 million, or ($0.32) per diluted share, compared with a net loss of $2.2 million, or ($0.41) per diluted share, a year earlier. Royalty revenue from TLANDO was $190,099, versus $122,849 in Q2 2025.
For the first half of 2026, total revenue was $309,496, consisting entirely of TLANDO royalties, compared with $716,713 in the prior-year period, which included $500,000 of license revenue. Net loss for the six months was $6.3 million, or ($0.84) per diluted share, versus $4.1 million, or ($0.76) per share, in 2025, reflecting higher research and development expenses of $4.8 million tied primarily to the LPCN 1154 Phase 3 study and increased personnel costs, as well as modestly higher general and administrative expenses. Lipocine continues to advance an oral therapeutics pipeline including LPCN 1154 for postpartum depression and several candidates targeting major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms and prevention of preterm birth.